Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.

Tom Little | Reuters

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.

Shares were last up 9.5% at 11:02 a.m. London time.

This is a developing story. Please check back for updates.

Source

World

Blue Owl calls off merger of its two private-credit funds after announcement rattles stock

November 19, 2025

Blue Owl has decided to call off the merging of two of its private-credit funds after the deal caused some angst among investors, according to people familiar with the matter. The firm had planned to merge its smaller, non-traded Blue Owl Capital Corporation II (OBDC II), into the larger, publicly traded fund Blue Owl Capital […]

World

Larry Summers resigns from OpenAI board after release of emails with Epstein

November 19, 2025

Larry Summers, president emeritus and professor at Harvard University, at the World Economic Forum (WEF) in Davos, Switzerland, on Tuesday, Jan. 21, 2025. Stefan Wermuth | Bloomberg | Getty Images Former Treasury Secretary Larry Summers said Wednesday that he will resign from the board at OpenAI after the release of emails between him and the notorious sex offender Jeffrey Epstein. Summers had announced […]

World

Dutch halt state intervention at Chinese-owned chipmaker Nexperia, paving way for exports to resume

November 19, 2025

This photograph shows a general view of Nexperia headquarters in Nijmegen on November 6, 2025. John Thys | Afp | Getty Images The Dutch government on Wednesday said it suspended its intervention at Chinese-owned chipmaker Nexperia, following constructive talks with Chinese authorities. “We see this as a show of goodwill,” Dutch Economy Minister Vincent Karremans […]